NUVB earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -15.43. Updated 2026-07-23.
Nuvation Bio (NUVB) Research Hub
Nuvation Bio (NUVB) trades on NYSE, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 6.07 USD (-6.90%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -15.43, market cap 2.12B. This hub links to the full technical, earnings and options research available for NUVB.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NYSE, US |
| Last close | 6.07 USD (-6.90%) |
| 52-week range | 4.87 USD – 7.58 USD |
| Trend regime | Range |
| 14-day RSI | 42.5 (Bearish) |
| Trailing P/E | -15.43 |
| Market cap | 2.12B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for NUVB
Covered Call on NUVB: how it works, illustrative setup around the real 6.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on NUVB: how it works, illustrative setup around the real 6.07 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on NUVB: how it works, illustrative setup around the real 6.07 USD price, max profit/loss, breakeven and when to use it. Educational.
NUVB technical analysis: range, last 6.07 USD, RSI 42.5, 52w range 4.87 USD–7.58 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is NUVB in?
Nuvation Bio (NUVB) is classified under Healthcare (Biotechnology), listed on NYSE, US.
Is NUVB in an uptrend or downtrend?
As of 2026-09-11, NUVB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is NUVB's trailing P/E ratio?
NUVB's trailing P/E is -15.43, with a market cap of 2.12B. See the earnings research page for full valuation detail.
When does NUVB next report earnings?
NUVB is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.15 USD.